Biotron Ltd has released a press release.
Quarterly Appendix 4C Cash Flow Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Biotron
- Biotron drug effective against covid-19 in animals
- Commencement of two pivotal BIT225 clinical trials
- Quarterly Cash Flow Report
- Full Year Statutory Accounts and Preliminary Final Report
- $1.4M R&D Tax Rebate
Later from Biotron
- BIT225 Effectiveness Against COVID-19 in Animals
- $1.56M R&D Rebate Received
- Quarterly Activities Report
- Quarterly Cash Flow Report Appendix 4C
- BIT225 effective against established sars-cov-2 in animals
Follow Biotron into a list and get an email when it puts out news.
Follow Biotron